Valeo Financial Advisors LLC acquired a new position in shares of Assembly Biosciences Inc (NASDAQ:ASMB) in the third quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 142,119 shares of the biopharmaceutical company’s stock, valued at approximately $4,963,000. Assembly Biosciences comprises approximately 1.1% of Valeo Financial Advisors LLC’s investment portfolio, making the stock its 14th biggest position. Valeo Financial Advisors LLC owned 0.71% of Assembly Biosciences at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Nationwide Fund Advisors purchased a new position in Assembly Biosciences during the 2nd quarter valued at about $161,000. Parametric Portfolio Associates LLC boosted its holdings in Assembly Biosciences by 13.6% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 1,203 shares during the period. Legal & General Group Plc purchased a new position in Assembly Biosciences during the 2nd quarter valued at about $212,000. Wells Fargo & Company MN purchased a new position in Assembly Biosciences during the 2nd quarter valued at about $213,000. Finally, Trexquant Investment LP purchased a new position in Assembly Biosciences during the 2nd quarter valued at about $217,000. 62.09% of the stock is owned by hedge funds and other institutional investors.
Assembly Biosciences Inc (ASMB) opened at $44.28 on Monday. Assembly Biosciences Inc has a 52 week low of $11.07 and a 52 week high of $52.37.
A number of brokerages recently commented on ASMB. ValuEngine cut Assembly Biosciences from a “hold” rating to a “sell” rating in a report on Thursday. BidaskClub upgraded Assembly Biosciences from a “hold” rating to a “buy” rating in a report on Friday, August 18th. Zacks Investment Research cut Assembly Biosciences from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Chardan Capital reiterated a “buy” rating on shares of Assembly Biosciences in a research note on Sunday, September 17th. Finally, Jefferies Group initiated coverage on Assembly Biosciences in a research note on Wednesday, November 8th. They issued a “buy” rating and a $50.00 price objective for the company. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $40.67.
In other news, Director William R. Ringo sold 1,000 shares of Assembly Biosciences stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $29.55, for a total value of $29,550.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 3,000 shares of company stock valued at $112,620 in the last quarter. Company insiders own 19.60% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://transcriptdaily.com/2017/12/11/valeo-financial-advisors-llc-invests-4-96-million-in-assembly-biosciences-inc-asmb.html.
Assembly Biosciences Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Want to see what other hedge funds are holding ASMB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Assembly Biosciences Inc (NASDAQ:ASMB).
Receive News & Ratings for Assembly Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.